BRAF mutation + MET amplification
|
CRC
|
BRAF mutation + MET amplification
|
CRC
|
vemurafenib + panitumumab Resistant: C4 – Case Studies
|
vemurafenib + panitumumab Resistant: C4 – Case Studies
|
BRAF mutation + MET amplification
|
CRC
|
BRAF mutation + MET amplification
|
CRC
|
crizotinib + vemurafenib Sensitive: C4 – Case Studies
|
crizotinib + vemurafenib Sensitive: C4 – Case Studies
|